ImmuCell CorporationICCCNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank21
Studio
Year-over-Year Change

Price-to-earnings ratio

Latest
-53.37
↑ 54% vs avg
Percentile
P21
Within normal range
Streak
2 yr
Consecutive declineElevated
Average
-116.96
Historical baseline
PeriodValueYoY Change
2025-53.37-173.7%
2024-19.50-187.4%
2023-6.79+64.2%
2022-18.94+97.6%
2021-775.80-1747.3%
2020-42.00-55.0%
2019-27.10-62.8%
2018-16.65+93.6%
2017-258.94-623.6%
201649.45-